Rockwell Medical (NASDAQ:RMTI) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Rockwell Medical (NASDAQ:RMTI) from a hold rating to a buy rating in a report released on Thursday morning.

RMTI has been the topic of a number of other research reports. Rodman & Renshaw assumed coverage on Rockwell Medical in a research note on Thursday, November 14th. They set a “buy” rating and a $5.00 price objective on the stock. HC Wainwright dropped their price target on shares of Rockwell Medical from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, November 25th. Finally, RODMAN&RENSHAW raised shares of Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th.

Rockwell Medical Trading Up 1.5 %

RMTI opened at $2.07 on Thursday. The business’s 50-day simple moving average is $3.06 and its 200 day simple moving average is $2.68. Rockwell Medical has a 52-week low of $1.16 and a 52-week high of $5.15. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RMTI. Armistice Capital LLC raised its stake in Rockwell Medical by 22.5% in the 2nd quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock valued at $5,670,000 after acquiring an additional 592,000 shares during the period. Jane Street Group LLC acquired a new position in shares of Rockwell Medical in the third quarter valued at $534,000. Walleye Capital LLC acquired a new position in shares of Rockwell Medical in the third quarter valued at $435,000. Renaissance Technologies LLC raised its position in shares of Rockwell Medical by 877.1% in the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after purchasing an additional 92,189 shares during the period. Finally, Corsair Capital Management L.P. acquired a new stake in shares of Rockwell Medical during the 3rd quarter worth about $298,000. 23.31% of the stock is currently owned by institutional investors.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.